美国急诊科使用有药物基因组学推荐药物的现状
该研究对2010-2015年美国国家医院门诊医疗调查(NHAMCS)进行横断面分析,评估急诊就诊中开具临床药物基因组学实施联盟(CPIC)A级或B级证据推荐药物的比例。在代表805,726,000次美国急诊就诊的165,155条记录中,148,243,000次就诊(18.4%)开具了CPIC药物,最常见为曲马多(6.3%)。涉及CPIC药物的就诊中女性、私人保险和自费患者比例较高,出院比例较高,而Medicare和Medicaid患者比例较低。作者认为,尽管基因分型的直接应用仍在发展中,急诊医护人员应了解并支持该技术,因其可能改善个体化、以患者为中心的诊疗。
要点
- 2010-2015年美国急诊就诊中18.4%(148,243,000/805,726,000)涉及至少一种CPIC A级或B级证据药物。
- 最常见的CPIC药物为曲马多,占急诊就诊的6.3%。
- 涉及CPIC药物的就诊中女性、私人保险和自费患者比例较高,Medicare和Medicaid患者比例较低。
- 涉及CPIC药物的就诊中从急诊出院的比例较高。
- 作者认为急诊医护人员应了解并支持药物基因组学技术,以潜在改善个体化诊疗。
适用人群与场景
- 2010-2015年美国急诊就诊人群(基于NHAMCS调查数据)。
诊断标准与关键阈值
- 药物基因组学推荐药物定义为CPIC推荐A级或B级证据的药物。
研究设计与关键结果
- 研究类型:2010-2015年NHAMCS横断面分析;样本:165,155条记录,代表805,726,000次美国急诊就诊。
- 主要结果:148,243,000次急诊就诊(18.4%)开具了至少一种CPIC A级或B级证据药物;最常见为曲马多(6.3%)。
- 次要比较:涉及CPIC药物的就诊中女性、私人保险和自费患者比例较高,Medicare和Medicaid患者比例较低,从急诊出院比例较高。
证据类型、等级与局限
- 证据类型:横断面分析;局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,尽管基因分型的直接应用仍在发展中,急诊医护人员应了解并支持该技术,因其可能改善个体化、以患者为中心的诊疗。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: Emergency departments (ED) use many medications with a range of therapeutic efficacy and potential significant side effects, and many medications have dosage adjustment recommendations based on the patient's specific genotype. How frequently medications with such pharmaco-genetic recommendations are used in United States (US) EDs has not been studied.
METHODS: We conducted a cross-sectional analysis of the 2010-2015 National Hospital Ambulatory Medical Care Survey (NHAMCS). We reported the proportion of ED visits in which at least one medication with Clinical Pharmacogenetics Implementation Consortium (CPIC) recommendation of Level A or B evidence was ordered. Secondary comparisons included distributions and 95% confidence intervals of age, gender, race/ethnicity, ED disposition, geographical region, immediacy, and insurance status between all ED visits and those involving a CPIC medication.
RESULTS: From 165,155 entries representing 805,726,000 US ED visits in the 2010-2015 NHAMCS, 148,243,000 ED visits (18.4%) led to orders of CPIC medications. The most common CPIC medication was tramadol (6.3%). Visits involving CPIC medications had higher proportions of patients who were female, had private insurance and self-pay, and were discharged from the ED. They also involved lower proportions of patients with Medicare and Medicaid.
CONCLUSION: Almost one fifth of US ED visits involve a medication with a pharmacogenetic recommendation that may impact the efficacy and toxicity for individual patients. While direct application of genotyping is still in development, it is important for emergency care providers to understand and support this technology given its potential to improve individualized, patient-centered care.
参考来源
- Limkakeng AT, Manandhar P, Erkanli A, et al. United States Emergency Department Use of Medications with Pharmacogenetic Recommendations. West J Emerg Med. 2021. PMID: 34787561. doi:10.5811/westjem.2021.5.51248
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。